MUC1 and adrenal cortex carcinoma: Interestingly, Avena et al. demonstrated that XCT790, an inverse agonist for estrogen receptor α, was able to reduce 3D spheroid formation and motility not only in H295R cells, but also in the mitotane-resistant MUC-1 model, suggesting that such an approach could be another effective option for the treatment of mitotane-resistant ACC [99].